Sheldon Koenig
Chief Executive Officer chez ESPERION THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Sheldon L.
Koenig is the founder of Nuvig Therapeutics, Inc. He is currently the President, Chief Executive Officer & Director at Esperion Therapeutics, Inc. since 2021.
Previously, he worked as the Vice President at Merck & Co., Inc. from 2009 to 2015 and as the Chief Commercial Officer & Executive VP at Portola Pharmaceuticals LLC from 2019 to 2020.
He also held the position of Senior VP & Head-Cardiovascular Franchise at Sanofi Corp.
Mr. Koenig completed his undergraduate degree at Drexel University and obtained an MBA from Monmouth University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/03/2024 | 766 816 ( 0,45% ) | 2 M $ | 31/03/2024 |
Postes actifs de Sheldon Koenig
| Sociétés | Poste | Début |
|---|---|---|
| ESPERION THERAPEUTICS, INC. | Chief Executive Officer | 18/05/2021 |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Founder | - |
Anciens postes connus de Sheldon Koenig
| Sociétés | Poste | Fin |
|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2015 |
| Sanofi Corp. | Corporate Officer/Principal | - |
Formation de Sheldon Koenig
| Drexel University | Undergraduate Degree |
| Monmouth University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ESPERION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
| Sanofi Corp. | |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
